Fundraising FoxExcelestar Ventures — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels.
BiotechHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Executive Officer)Raymond Lareau(Executive Officer)inSteven Cagnetta(Executive Officer)Sean Boyle(Chief Executive Officer)in
BoardHenry Chen(Director)in
Board seatTasneem Dohadwala· per SEC Form D
Co-investorsAngel Physicians FundAscension VenturesCatalyst Health VenturesDelos CapitalSparta Group
Neurolutions makes IpsiHand, an FDA-cleared brain-computer interface system for at-home motor rehabilitation of chronic stroke survivors with arm and hand weakness.
BiotechDigital HealthHealthtechMedical DevicesVan Nuys, US
Eric Leuthardt(Director)inLeo Petrossian(Executive Officer, Director)in
BoardYuanwei Tai(Director)Kevin Reilly(Director)inFred Khosravi(Director)inStavros Vizirgianakis(Director)
Co-investorsAlly Bridge GroupAmed Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.